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Abstract
Objective To assess patients’ outcomes after subacromial or
glenohumeral injections based on the degree of lateral exten-
sion of the acromion.
Methods 307 patients were prospectively included after ther-
apeutic fluoroscopy-guided subacromial (n=148) or
glenohumeral (n=159) injections with anaesthetic and long-
acting corticosteroids. Pre- and post-injection outcomes at
1 week and 1 month were obtained using the 11-point numer-
ical rating scale (NRS) for pain. Lateral extension of the
acromion was quantified and categorized by the critical
shoulder angle (CSA) and the acromion index (AI) on
anteroposterior conventional radiographs.
Results Patients’ outcomes at 1 week and 1 month were
significantly improved (p<0.001) compared to baseline for
subacromial and glenohumeral injection patients. Patients
with a CSA <35° showed significantly higher pain reduction
1 month after subacromial injection compared to patients with
a CSA >35° (4.2±2.6 vs. 3.2±3.0, p=0.04). A significant
difference in the 1-month NRS change in pain scores is noted
for smaller AIs after subacromial injection (4.3±2.8 vs.
2.6±2.9; p=0.01). No significant association was noted
between clinical outcome and the lateral extension of the
acromion after glenohumeral joint injections.
Conclusions A short lateral extension of the acromion was
associated with better clinical outcomes in subacromial injec-
tion patients but not in glenohumeral injection patients.
Key Points
• Patients’ outcomes at 1 month improved significantly com-
pared to baseline for subacromial injections
• Patients’ outcomes at 1 month improved significantly com-
pared to baseline for glenohumeral injections
• Short acromial lateralization was associated with better
clinical outcome after subacromial injection
• The acromial lateralization was not associated with clinical
outcome after glenohumeral injection
Keywords Conventional radiograph . Shoulder .
Subacromial impingement syndrome . Triamcinolone .
Intra-articular injection
Abbreviations and Acronyms
NRS Numerical rating scale
CSA Critical shoulder angle
AI Acromion index
ICC Intraclass correlation coefficient
SD Standard deviation
Introduction
Avariety of shoulder pathologies such as osteoarthritis, adhe-
sive capsulitis (frozen shoulder), SLAP lesion (superior labral
tear from anterior to posterior), shoulder pain from unknown
aetiology, or impingement syndrome are frequently treated by
injections with local anaesthetics and corticosteroids into the
subacromial bursa and/or the glenohumeral joint [1–6].
However, the research evidence for shoulder pain manage-
ment with imaging-guided therapeutic joint injections for
conditions other than inflammatory arthropathies has been
shown to be limited [5, 7]. The reason for this lack of strong
research evidence supporting the effectiveness of these
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injections may be that they are often used without a specific
diagnosis or cause for the symptoms.
A large lateral extension of the acromion, as noted on true
anteroposterior radiographs of the shoulder made with the arm
in neutral position, has been shown to be associated with rotator
cuff tears [8, 9], whereas a short lateral extension of the
acromion with an inferiorly inclined glenoid has been related
to glenohumeral osteoarthritis [9]. Consequently, the lateral
extension of the acromion is associated with impingement-
related disorders as well as intra-articular pathologies such as
osteoarthritis. According to Neer’s article from 1972, shoulder
impingement includes the diagnoses of subacromial bursitis,
tendinopathy, and partial and full-thickness tearing of the rota-
tor cuff [10]. Thus this relatively simple imaging evaluation [9]
may also be relevant in determining which imaging-guided
therapeutic injection procedure would be more appropriate
based on patient responses to these treatments. Shoulder im-
pingement patients may be managed by subacromial injections
[2, 3], whereas symptoms arising from the glenohumeral joint
may be treated by intra-articular injection [6, 11–13].
It was hypothesized that different extents of acromial cov-
erage might influence patients’ outcomes after therapeutic
subacromial or glenohumeral injections using local anaes-
thetics and long-acting corticosteroids.
Thus the purpose of this study was to compare patients’
outcomes after subacromial or glenohumeral injections based
onmeasurements and categorization of the lateral extension of
the acromion.
Materials and methods
Study design and population
This was a prospective outcome study of consecutive patients
from two different patient cohorts. One group had imaging-
guided therapeutic subacromial injections and the other group
had imaging-guided therapeutic glenohumeral joint injections.
Ethical approval was obtained from the Institutional and
Cantonal Review Boards for this study. Patients provided
signed informed consent before the therapeutic fluoroscopy-
guided injection with long-acting corticosteroids.
Patients with previous surgery of the ipsilateral shoulder
and patients with contrast leakage into the glenohumeral joint
on the subacromial bursogram or in the subacromial bursa
on the shoulder arthrograms as proof of a full thickness
tear of the rotator cuff or on available magnetic reso-
nance imagining (MRI) were excluded [14–16]. Patients
with multiple injections into the same shoulder such as
subacromial, glenohumeral, and acromioclavicular injections
within 1 month were also excluded. In total, 100 patients in
the subacromial injection group and 88 patients in the
glenohumeral injection group were excluded. A total of 307
patients with complete outcome-based questionnaire data and
available conventional radiographs were prospectively includ-
ed in the present study after applying the exclusion criteria.
148 patients were included after receiving subacromial injec-
tions and 159 patients after receiving glenohumeral infiltra-
tions between January 2010 and March 2013.
Injection procedure
Fellowship-trained shoulder surgeons from the orthopaedic
surgery department at our institution obtained patients’ med-
ical histories and physical examinations. Subacromial shoul-
der impingement was the indication for subacromial injec-
tions. Shoulder impingement was diagnosed by Neer's sign,
Hawkin's test, and the painful arc test [10, 17, 18]. Patients
with clinical symptoms for an intra-articular source of pain
such as adhesive capsulitis (frozen shoulder), biceps-related
disorders (tendinopathy and SLAP lesion [superior labral
tear from anterior to posterior]), or osteoarthritis of the
glenohumeral joint were referred for glenohumeral joint injec-
tion [19–21]. All therapeutic subacromial or glenohumeral
injections were performed under fluoroscopy guidance using
sterile conditions by one of five fellowship-trained musculo-
skeletal radiologists or by one of three board-certified radiol-
ogists during their musculoskeletal radiology fellowship pro-
gramme. The correct location of the needle tip was confirmed
by iodinated contrast agent (iopamidol, 200 mg of iodine/ ml;
Bracco, Milan, Italy) and documented by a conventional ra-
diograph. Anterior portals were used for both the subacromial
(Fig. 1) and glenohumeral injections (Fig. 2). The needle tip
was directed inferolaterally to the undersurface of the
acromion process followed by a subacromial bursogram for
the subacromial injection (Fig. 1). The needle tip was directed
towards the cartilage surface of the humeral head superomedial
followed by a conventional arthrogram for the glenohumeral
injection (Fig. 2). Subsequently long-acting corticosteroids
(40 mg of triamcinolone acetonide; Helvepharm AG,
Fig. 1 A 53-year-old woman with subacromial shoulder impingement
underwent subacromial infiltration. The radiograph demonstrates the
correct position of the injection needle tip (open white arrow) and typical
subacromial contrast agent distribution (bold white arrow). The curved
black arrow indicates the connection tube between the syringe (not
shown) and the injection needle
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Frauenfeld, Switzerland) and 2–5 ml of local anaesthetic (li-
docaine hydrochloride 2 %; Sintetica SA, Mendrisio,
Switzerland) were injected.
Baseline data and outcome measures
Patients’ outcomes from the subacromial and glenohumeral
injections were assessed by asking all patients to complete the
11-point numerical rating scale (NRS) for pain, where 0
indicates no pain and 10 indicates the worst pain imaginable.
The NRS pain levels were obtained before the injection, at
1 week, and at 1 month post-injection.
Conventional radiographs
Conventional radiographs of the shoulder consisted of the
anteroposterior (AP), axial, and Neer’s projections, as this is
the standard procedure in our institution. Anteroposterior views
served exclusively in the present investigation for the measure-
ments and were acquired with a digital radiography system
(Ysio, Siemens Healthcare, Erlangen, Germany) and the follow-
ing exposure parameters: detector area of 35×43 cm; neutrally
rotated arm; 20° craniocaudal angulation of the x-ray beam;
patients in the standing position; no use of a grid; typical value
of tube voltage, 61.5 kVp; automatic exposure for tube current
(typical value: 50 mAs); detector-to-tube distance, 150 cm.
Quantification of lateral extension of the acromion process
on radiographs
The lateral extension of the acromion was quantified on the
radiographs using two different measurement methods. One
was the so-called critical shoulder angle (CSA) [9] and the
other was the acromion index (AI) [8]. The CSA was mea-
sured as the angle between the glenoid plane and the line from
the inferior osseous margin of the glenoid plane and the lateral
aspect of the acromion [9] (Figs. 3a and 4a). The measure-
ments were then assigned to one of two categories: <35° and
>35°. The AI [8] was determined as the ratio of the distance
from the glenoid plane to the acromion process (GA) and the
distance from the glenoid plane to the lateral aspect of the
humeral head (GH): AI = GA/GH (Figs. 3b and 4b) [8]. The
AI numerical values were assigned to one of three categories:
<0.64, 0.64 – 0.73, and >0.73. The larger the lateral extension
of the acromion, the higher the critical shoulder angle and the
AI [8, 9].
One staff radiologist (TJD, observer 1) performed both the
AI and critical shoulder angle measurements for all patients in
both injection groups. One of two staff orthopaedic surgeons
measured the critical shoulder angle (BKM, observer 2) or the
Fig. 2 A 54-year-old man with partial articular-sided supraspinatus
tendon avulsion (PASTA) lesion underwent glenohumeral infiltration.
Radiograph shows the contrast agent distribution within the
glenohumeral joint space (bold white arrow) and the posterior joint recess
(open white arrow)
Fig. 3 A 55-year-old man with osteophytes (a, bold white arrow) and
moderate radiographic joint space narrowing inferiorly indicative of
osteoarthritis of the glenohumeral joint. The critical shoulder angle α
(CSA, A) of 22° and the acromion index (AI) of 0.57 (b, AI = ratio
between distance GA and GH) represent the short lateral extension of the
acromion process, which has been related to osteoarthritis of the
glenohumeral joint
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AI (GJP, observer 3) to assess the interobserver agreement.
Measurements were acquired on a picture archiving and com-
munication system (PACS) workstation (AGFA Impax
6.4.0.4551, Agfa HealthCare, Mortsel, Belgium).
Statistical analysis
The baseline to 1 week and baseline to 1 month NRS change
in pain scores were calculated and compared for the measure-
ment categories using the t-test for the CSA categories and the
ANOVA test for the AI categories. A p-value <0.05 was
considered to indicate a statistically significant difference
between the groups.
Interobserver reliability of the measurement procedures
was assessed using the Intraclass correlation coefficient for
the numerical values and the Kappa statistic for the two
measurement procedures. A software package was used for
the calculations (SPSS Statistics for Windows Version 21.0,
IBM Corp, Armonk, NY, USA).
Results
General outcomes for subacromial and glenohumeral joint
injections
Table 1 lists the baseline numerical rating scale for pain scores
and patients’ outcome at 1 week and 1 month. Patients’
baseline pain assessed by the numerical rating scale for pain
was 6.4±1.9 for subacromial injection patients and 6.2±2.2
for glenohumeral injection patients. Patients’ pain at 1 week
and 1 month was significantly lower (p<0.001) compared to
baseline for both study populations, the subacromial and the
glenohumeral injection groups. The NRS for pain values at
1 week were 2.9±2.3 (NRS Change Score: 3.5±2.6) for the
subacromial injection group and 3.2±2.3 (NRS Change
Score: 2.9±2.4) for the glenohumeral injection group. The
corresponding NRS values at 1 month were 2.6±2.5 (NRS
Change Score: 3.8±2.8) for the subacromial injection group
and 2.7±2.3 (NRS Change Score: 3.4±2.6) for the
glenohumeral injection group.
Lateral extension of the acromion on radiographs
The mean CSA in patients having subacromial infiltrations for
observer 1 was 33.6° (SD=3.8) with a range of 23.7–40.4°
and for observer 2 it was 33.5° (SD=3.6) with a range of
24.4–39.6°. The mean AI for subacromial infiltration patients
as measured by observer 1 was 0.68 (SD=0.07) with a range
of 0.50–0.79. For the glenohumeral infiltration group the
mean CSA as measured by observer 1 was 32.8° (SD=4.0)
with a range of 20.5–44.7° and for observer 3 it was 32.0°
(SD=4.2) with a range of 19.0–45.8°. The mean AI was 0.67
(SD=0.07) and a range of 0.43–0.87 for observer 1. The
corresponding mean AI for observer 3 was 0.66 (SD=0.08)
with a range of 0.41–0.90.
Fig. 4 A 40-year-old man with subacromial shoulder impingement. The
critical shoulder angle β (CSA, a) of 37° and the acromion index (AI) of
0.76 (b, AI = ratio between distance GA and GH) are indicative of a large
lateral extension of the acromion process, which has been shown to be
associated with rotator cuff tears
Table 1 Comparison of numerical rating scale (NRS) pain scores and
NRS change in pain scores at 1 week and 1 month post-injection for all






Baseline NRS ± SD 6.4±1.9 6.2±2.2
1 Week NRS ± SD 2.9±2.3* 3.2±2.3*
1 Month NRS ± SD 2.6±2.5* 2.7±2.3*
1 Week NRS change
score ± SD
3.5±2.6 2.9±2.4
1 Month NRS change
score ± SD
3.8±2.8 3.4±2.6
An asterisk (*) indicates that patients’ outcomes improved significantly (p
<0.001) at both 1 week and 1 month compared to baseline
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Interobserver agreement
Interobserver agreement critical shoulder angle
The inter-rater reliability of measuring the critical shoulder
angle as tested using the intraclass correlation coefficient
(ICC) was almost perfect with a mean of 0.94 (95 % CI=
0.92–0.96). Similarly the inter-rater reliability of categorizing
these measurements as evaluated using the Kappa statistic was
also ‘almost perfect’ with a Kappa value of 0.91.
Interobserver agreement acromion index
The inter-rater reliability of measuring the AI using the ICC
was also almost perfect with a mean of 0.96 (95 % CI=0.94–
0.97). Assessing the inter-rater reliability of categorizing the
AI using the Kappa statistic found substantial agreement with
a Kappa value of 0.77.
Subacromial injection outcome for different categorizations
of the lateral extension of the acromion
Baseline NRS pain scores for the subacromial injection
groups (Tables 2 and 3) revealed no significant differences,
either between the two CSA categories or between the three
categories of the AI. However, comparing the NRS change
scores found a significant difference at 1 month with CSAs of
<35° showing significantlymore pain reduction (Table 2) after
subacromial injection. In addition, a significant difference in
the 1-month NRS change scores for the AI is noted, with
category 3 patients having the lowest change in pain score
while category 2 patients had the highest pain decrease after
subacromial injection (Table 3).
Glenohumeral injection outcome for different categorizations
of the lateral extension of the acromion
There were no statistically significant differences after
glenohumeral injection either between the two CSA categories
or between the three AI categories for pre-injection baseline or
the follow-up NRS change in pain scores (Tables 2 and 3).
Discussion
The purpose of the present study was to compare specific
findings on routine shoulder radiographs with outcomes from
imaging-guided therapeutic subacromial and glenohumeral
injections in an attempt to better predict which patients may
respond more favourably to this treatment and to explore how
anatomical variations may contribute to specific clinical
symptoms. The results from this study support a relationship
between anatomical differences and outcomes from these
injections, particularly for patients having subacromial thera-
peutic injections. Specifically, patients with a short lateral
extension of the acromion on anteroposterior radiographs of
the shoulder showed a significantly higher pain reduction after
subacromial injection when compared to patients with a large
lateral extension of the acromion. The fact that the inter-rater
reliability of the CSA and AI measurements was so high is
reassuring, showing that these two measurements are easily
reproducible.
The hypothesis as to why subacromial injection patients
have better outcomes with the shorter acromion process is that
patients with a larger lateral extension of the acromion (CSA
of >35°, AI of >0.73) are more prone to rotator cuff tears due
to the relative length of the acromion process impinging upon
the structures inferiorly [8, 9]. Prior to the presence of a tear,
the patient would likely experience clinical signs of impinge-
ment and therefore more likely be referred for a subacromial
injection rather than a glenohumeral injection.
One recent publication [22] reported specific abnormalities
detected on routine radiographs that are associated with better
outcome from therapeutic subacromial injections in a smaller
study population. However, the CSA was not assessed in that
study. These types of studies comparing treatment outcomes
with specific imaging findings can help referring clinicians in
advising patients as to what to expect from various interventions,
Table 2 Comparison of baseline numerical rating scale (NRS) pain scores andNRS change in pain scores at 1 week and 1month post-injection between
the two categories of the critical shoulder angle (CSA) for subacromial injection patients and glenohumeral injection patients
Subacromial injection Glenohumeral injection
CSA Cat. 1 CSA Cat. 2 p value CSA Cat. 1 CSA Cat. 2 p value
(<35°) (>35°) (<35°) (>35°)
(n=96) (n=52) (n=123) (n=36)
Baseline NRS ± SD 6.3±1.8 6.5±2.1 0.50 6.2±2.2 6.0±1.9 0.57
1 Week NRS change score ± SD 3.7±2.6 3.2±2.5 0.25 2.8±2.5 3.3±1.9 0.34
1 Month NRS change score ± SD 4.2±2.6 3.2±3.0 0.04 3.3±2.7 3.6±2.4 0.55
SD standard deviation
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based on their particular imaging findings. Individual quantita-
tive anatomymay be related to biomechanics that induce specific
types of degenerative joint disorders such as glenohumeral oste-
oarthritis or rotator cuff tears [9]. An upward facing plane of the
glenoid, the so-called glenoid inclination on anteroposterior
radiographs, was associated with rotator cuff tears [23] and
superior humeral head migration [24]. It was hypothesized that
superior humeral head migration may cause impingement of the
supraspinatus tendon [24]. A large lateral extension of the
acromion was associated with full-thickness tears of the
supraspinatus tendon [8, 9]. Nyfeller et al. [8] speculated that a
larger lateral extension of the acromion might increase the as-
cending deltoid muscle force vector to the humerus as a potential
aetiology of subacromial impingement and degenerative chang-
es of the supraspinatus tendon. A smaller lateral extension of the
acromion might increase the compressive force to the humeral
head against the glenoid cavity, thus a smaller lateral extension
might predispose to degenerative changes of the glenohumeral
joint [8]. The CSA measurement covers two factors associated
with rotator cuff tears, the large lateral extension of the acromion
as well as the increased inclination of the glenoid [9].
In contrast to the CSA, the AI measurement does not
integrate the inclination of the glenoid [9]. In addition, osteo-
arthritis misleadingly increases the AI due to the flattening of
the humeral head and narrowing of the radiographic joint
space [8, 9]. A short lateral extension of the acromion assessed
by the critical shoulder angle as well as the AI was associated
with a significantly better outcome after subacromial injec-
tion. However, no difference was found after glenohumeral
injections in the present study.
Separate measurements of the lateral extension of the
acromion by the AI as well as the glenoid inclination did not
reveal significant differences in clinical improvement after
image-guided subacromial injections in a previous study in-
cluding 98 patients [22]. Nevertheless, the published data in
that study demonstrated a trend for better clinical outcomes in
patients with a smaller lateral extension of the acromion [22].
However, patients with different glenoid inclinations in that
same study revealed very similar clinical outcomes [22], and
the authors used a robust and reproducible measurement
method for the glenoid inclination measurements [22, 25].
The authors [22] also did not find a significant difference in
clinical improvement after subacromial injections between
patients with and without an os acromiale, the various
acromial shapes according to Bigliani classification, a lateral
down-sloping acromion, reduced acromiohumeral distance,
anterior or lateral acromial spurs and osteophytes of the
glenohumeral and acromioclavicular joint on conventional
radiographs.
In general, the outcomes for glenohumeral injection pa-
tients in the categories of the two measurements were not
significant or perhaps not as interesting compared to those
from the subacromial injection patients; however, the
glenohumeral injection patients may serve as a control group
for the subacromial injection patients in the present investiga-
tion. Additional imaging findings, including the presence or
absence and severity of glenohumeral osteoarthritis, com-
pared to outcomes should be investigated to test the hypoth-
esis that patients with a critical shoulder angle <30° are more
likely to have osteoarthritis.
Limitations
One limitation of this study is that the presence of various
degrees of other shoulder impingement-related radiological
parameters, osteoarthritis, adhesive capsulitis (frozen shoul-
der), SLAP lesion, other sources of shoulder pain, patients’
age, and adjunctive therapy such as physiotherapy or NSAIDs
were not analysed. Only 1-month outcomes were collected
rather than longer term outcome data. The pharmacokinetics
of triamcinolone after intra-articular and intramuscular admin-
istration have shown that absorption of triamcinolone from the
injection site is complete after a period of 2–3 weeks with a
similar duration of action [19, 26–28]. Other factors as
discussed above might have a stronger influence on outcome
at a longer follow-up period than 1 month. However, the
purpose of the study was to evaluate the clinical outcomes
after subacromial and glenohumeral injections for different
extents of acromial coverage using a simple, highly reproduc-
ible tool on conventional radiographs [9].
Table 3 Comparison of baseline numerical rating scale (NRS) pain scores andNRS change in pain scores at 1 week and 1month post-injection between
the three categories of the Acromial Index (AI) for subacromial injection patients and glenohumeral injection patients




















Baseline NRS ± SD 6.1±1.8 6.5±2.1 6.6±1.7 0.42 5.9±2.2 6.5±2.2 6.0±1.9 0.28
1 Week NRS change score ± SD 3.5±2.7 3.9±2.5 2.7±2.5 0.08 2.7±2.7 3.0±2.3 3.3±2.0 0.28
1 Month NRS change score ± SD 3.9±2.6 4.3±2.8 2.6±2.9 0.01 3.2±2.7 3.4±2.7 3.6±2.4 0.56
SD standard deviation
272 Eur Radiol (2015) 25:267–273
Conclusions
Our hypothesis that different extents of acromial coverage
might influence patients’ outcome after therapeutic
subacromial or glenohumeral injections was disproved for
glenohumeral injections and confirmed for subacromial
injections.
A short lateral extension of the acromion was associated
with a better clinical outcome in subacromial injection patients
but not in glenohumeral injection patients.
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